mipomersen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antisense oligonucleotides	4747	629167-92-6

Description:

Molecule

Description

Synonyms:

mipomersen
mipomersen sodium
kynamro
ISIS 301012
ISIS-301012

an antisense oligonucleotide that binds apolipoprotein B mRNA and inhibits expression of apoB

Molecular weight: 7594.76
Formula: C230H305N67Na19O122P19S19
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 2603.20
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.67 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	17.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 29, 2013	FDA	GENZYME CORP

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site pain	83.00	60.87	26	232	129812	79614318

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AX11	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Other lipid modifying agents
FDA CS	M0025055	Oligonucleotides, Antisense
FDA PE	N0000008841	Decreased Protein Synthesis
MeSH PA	D000924	Anticholesteremic Agents
MeSH PA	D000963	Antimetabolites
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents
MeSH PA	D015335	Molecular Probes
MeSH PA	D020319	Oligodeoxyribonucleotides, Antisense
MeSH PA	D016376	Oligonucleotides, Antisense
FDA EPC	N0000191626	Antisense Oligonucleotide
FDA EPC	N0000191627	Apolipoprotein B-100 Synthesis Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Familial hypercholesterolemia - homozygous	indication	238078005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
9GJ8S4GU0M	UNII
D08946	KEGG_DRUG
4032221	VUID
N0000186782	NUI
4032221	VANDF
4032222	VANDF
C2604635	UMLSCUI
CHEMBL2219536	ChEMBL_ID
DB05528	DRUGBANK_ID
CHEMBL502097	ChEMBL_ID
8946	INN_ID
C524142	MESH_SUPPLEMENTAL_RECORD_UI
7364	IUPHAR_LIGAND_ID
1367838	RXNORM
198505	MMSL
29108	MMSL
d07973	MMSL
014906	NDDF
014907	NDDF
716221002	SNOMEDCT_US
716222009	SNOMEDCT_US
1000120-98-8	SECONDARY_CAS_RN
44564107	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Kynamro	HUMAN PRESCRIPTION DRUG LABEL	1	70688-0502	INJECTION, SOLUTION	200 mg	SUBCUTANEOUS	NDA	2 sections